Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has completed the final treatment study visit of the lead-in study and remained compliant with the lead-in protocol and study treatment.~* The patient has provided written informed consent to participate in this extension protocol.~* Female patients of childbearing potential continue to agree to practice one of the medically acceptable methods of birth control detailed in the lead-in study.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL (Type: EXPERIMENTAL): 2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).